Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283735 | 0.86 | SIGMAR1 (0.81) | SIGMAR1GAAMAPTKCNH2CA12 | |
| Hydrochloric Acid SCHEMBL6895868 | 0.85 | SIGMAR1 (0.52) | SIGMAR1GAAMAPTKCNH2CA12 | |
| SCHEMBL13937400 | 0.84 | SIGMAR1 (0.77) | SIGMAR1GAAMAPTKCNH2CA12 | |
| Hydrochloric Acid SCHEMBL5028920 | 0.84 | SIGMAR1 (0.77) | SIGMAR1GAAMAPTKCNH2CA12 | |
| SCHEMBL8140699 | 0.84 | SIGMAR1 (0.77) | SIGMAR1GAAMAPTKCNH2CA12 | |
| Hydrochloric Acid SCHEMBL6898327 | 0.82 | SIGMAR1 (0.57) | SIGMAR1GAAMAPTKCNH2ATM | |
| Hydrochloric Acid SCHEMBL6896622 | 0.80 | SIGMAR1 (0.55) | SIGMAR1GAAMAPTKCNH2 | |
| SCHEMBL8358627 | 0.80 | SIGMAR1 (0.66) | SIGMAR1GAAMAPTCA2 | |
| SCHEMBL11370850 | 0.80 | MEN1 (0.70) | SIGMAR1GAAMAPT | |
| SCHEMBL9768701 | 0.79 | SIGMAR1 (0.86) | SIGMAR1GAAMAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | SIGMAR1 26/4885GAA 2480/4885MAPT 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.